Show simple item record

dc.contributor.authorCurtis, Den_US
dc.date.accessioned2018-09-19T14:32:42Z
dc.date.available2018-07-25en_US
dc.date.issued2018-10en_US
dc.date.submitted2018-09-13T11:20:59.451Z
dc.identifier.other10.1101/287136
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/44783
dc.description.abstractBACKGROUND: The polygenic risk score (PRS) for schizophrenia, derived from very large numbers of weakly associated genetic markers, has been repeatedly shown to be robustly associated with schizophrenia in independent samples and also with other diseases and traits. AIM: This study aims to explore the distribution of the schizophrenia PRS in subjects of different ancestry. METHODS: The schizophrenia PRS derived from the large genome-wide association study carried out by the Psychiatric Genetics Consortium was calculated using the downloaded genotypes of HapMap subjects from 11 different ancestral groups. It was also calculated using downloaded genotypes of European schizophrenia cases and controls from the CommonMind Consortium. RESULTS: The PRS for schizophrenia varied significantly between ancestral groups (P<2×10(-16)) and was much higher in African than European HapMap subjects. The mean difference between these groups was 10 times as high as the mean difference between European schizophrenia cases and controls. The distributions of scores for African and European subjects hardly overlapped. CONCLUSION: The PRS cannot be regarded as simply a measure of the polygenic contribution to risk of schizophrenia and clearly contains a strong ancestry component. It is possible that this could be controlled to some extent by incorporating principal components as covariates, but doubts remain as to how it should be interpreted. The PRS derived from European subjects cannot be applied to non-Europeans, limiting its potential usefulness in clinical settings and raising issues of inequity in health provision. Previous studies that have used the PRS should be re-examined in the light of these findings.en_US
dc.description.sponsorshipThe CommonMind Consortium data generation was supported by funding from Takeda Pharmaceuticals Company Limited, F. Hoffman-La Roche Ltd and NIH grants R01MH085542, R01MH093725, P50MH066392, P50MH080405, R01MH097276, RO1-MH-075916, P50M096891, P50MH084053S1, R37MH057881 and R37MH057881S1, HHSN271201300031C, AG02219, AG05138 and MH06692.en_US
dc.format.extent85 - 89en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofPsychiatr Geneten_US
dc.rightsAll rights reserved. No reuse allowed without permission
dc.rights2018. The author
dc.subjectAdulten_US
dc.subjectAfrican Continental Ancestry Groupen_US
dc.subjectCase-Control Studiesen_US
dc.subjectContinental Population Groupsen_US
dc.subjectDatabases, Geneticen_US
dc.subjectEuropean Continental Ancestry Groupen_US
dc.subjectFemaleen_US
dc.subjectGenetic Predisposition to Diseaseen_US
dc.subjectGenome-Wide Association Studyen_US
dc.subjectGenotypeen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMultifactorial Inheritanceen_US
dc.subjectPolymorphism, Single Nucleotideen_US
dc.subjectRisk Factorsen_US
dc.subjectSchizophreniaen_US
dc.titlePolygenic risk score for schizophrenia is more strongly associated with ancestry than with schizophrenia.en_US
dc.typeArticle
dc.identifier.doi10.1097/YPG.0000000000000206en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/30160659en_US
pubs.issue5en_US
pubs.notesNo embargoen_US
pubs.publication-statusPublisheden_US
pubs.volume28en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record